BioCentury | Sep 11, 2020
Product Development

Sept. 10 Quick Takes: approvals for Zai, GSK and Phase III readouts for Satsuma, Amryt and Takeda; plus Houston Methodist, MassBio and JPM

China approves Zejula as first-line maintenance for ovarian cancerChina's National Medical Products Administration (NMPA) approved an sNDA from Zai Lab Ltd. (NASDAQ:ZLAB) for Zejula niraparib as a first-line maintenance therapy in ovarian cancer patients in...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | Jun 4, 2019
Distillery Techniques

Tool compounds for probing the role of human cGAS in inflammatory diseases

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compound Small molecule inhibitors of human cGAS could be used to probe the role of cGAS-dependent signaling in inflammatory diseases. Screening of a compound library followed by optimization of the...
BioCentury | Jan 15, 2019
Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
BioCentury | Jan 14, 2019
Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
BioCentury | Nov 29, 2018
Translation in Brief

Predicting respiratory response

A University of California San Francisco team has described a gene signature that identifies a subgroup of chronic obstructive pulmonary disease (COPD) patients who could benefit from IL-17A inhibitors if they don’t respond to corticosteroids....
BioCentury | Nov 16, 2018
Clinical News

Theravance secures U.S. approval for Yupelri in COPD

Theravance Biopharma Inc. (NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL) said FDA approved Yupelri revefenacin as a maintenance treatment of chronic obstructive pulmonary disease. Yupelri marks the first once-daily nebulized bronchodilator to receive U.S. approval for...
BioCentury | Nov 9, 2018
Company News

Theravance secures U.S. approval for Yupelri in COPD

Theravance Biopharma Inc. (NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL) said FDA approved Yupelri revefenacin as a maintenance treatment of chronic obstructive pulmonary disease. Yupelri marks the first once-daily nebulized bronchodilator to receive U.S. approval for...
BioCentury | Sep 21, 2018
Clinical News

AZ says Phase IIIb data of Bevespi Aerosphere in COPD are 'inconsistent with previous data'

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Bevespi Aerosphere glycopyrrolate/formoterol fumarate met one of three primary endpoints in the Phase IIIb AERISTO trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere was...
BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 318